For research and educational purposes only. Not intended for human consumption.
Sermorelin
Well Researched- •1.26kg lean mass gains in elderly (16-week study)
- •Cognitive function improvement data updated
- •Ipamorelin synergy protocols documented
GHRH 1-29 Analog | Growth Hormone Releasing Hormone
Overview
What is Sermorelin?
Sermorelin acetate is a 29-amino acid synthetic analog of human growth hormone-releasing hormone (GHRH), FDA-approved in 1997 for pediatric growth hormone deficiency (discontinued 2008 for manufacturing reasons, not safety). Research continues to explore its effects on body composition, cognitive function, and metabolic health in adults, with studies showing 1.26kg lean mass gains in elderly subjects over 16 weeks. Banned by WADA
Key Benefits
FDA-proven efficacy, 6% bioavailability, maintains natural GH pulses, preserves pituitary function. Research shows potential to 'partially ameliorate' cognitive declines from GH/IGF-1 deficiency. Available through compounded formulations with prescription.
Mechanism of Action
Subcutaneous injection provides optimal bioavailability with rapid onset (5-20 minutes) and physiological pulsatile GH stimulation. Works by enhancing body's natural hormone production rather than replacing hormones directly, considered safer alternative to direct HGH therapy.
Molecular Information
Pharmacokinetics
Research Indications
Lean Body Mass Enhancement
1.26 kg lean mass increase documented in elderly men with improved muscle strength tests.
IGF-1 Mediated Growth
Stimulates endogenous IGF-1 production leading to muscle protein synthesis.
Athletic Performance Support
Enhanced recovery and muscle development through physiological GH stimulation.
Research Protocols
Disclaimer: Sermorelin was FDA-approved but discontinued for manufacturing reasons, not safety concerns. These are commonly discussed protocols. Consult a healthcare provider before use.
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Anti-aging/Longevity | 200-300mcg daily | Once at bedtime | Subcutaneous injection |
| Athletic Performance | 300-500mcg daily | Once at bedtime | Subcutaneous injection |
| Pediatric GH Deficiency | 30mcg/kg daily | Once at bedtime | Subcutaneous injection |
| Body Composition | 200mcg daily | 5 days weekly | Subcutaneous injection |
| Combination Therapy | 200mcg + GHRP | Once daily | Subcutaneous co-injection |
Timing: Bedtime administration aligns with natural nocturnal GH pulses. Avoid food 2+ hours before injection as carbohydrates blunt GH response.
Peptide Interactions
How to Reconstitute
Important: Always use bacteriostatic water (BAC). Sterile technique is essential.
Allow sermorelin vial to reach room temperature before reconstitution
Clean vial top with alcohol swab and allow to dry
Inject 3mL bacteriostatic water slowly against vial wall (not directly onto powder)
Gently swirl vial in circular motion - do not shake vigorously to avoid foaming
Allow to sit for 2-3 minutes until powder completely dissolves into clear solution
Store reconstituted solution at 2-8°C and use within 10-30 days
Inject subcutaneously at 45-degree angle rotating sites
Dosing Calculator
Calculate your injection volume with visual dosing guide
To obtain 250 mcg from this solution:
Draw 0.10 mL=10 units
(1 mL = 100 units on any insulin syringe)
Draw to this mark for 250 mcg
This calculator is for research purposes only. Always verify calculations and consult protocols.
Quality Indicators
Clear Reconstituted Solution
Should be completely clear and colorless without particles, cloudiness, or precipitation.
Pharmaceutical Grade Purity
Greater than 98% peptide purity per USP standards.
Proper Cold Chain Storage
Maintained at 2-8°C throughout transport with protection from light.
FDA-Registered Manufacturing
Produced in FDA-registered facilities following cGMP.
Cloudy or Discolored Solution
Any cloudiness, particles, or color changes indicates degradation.
Room Temperature Exposure
Brief room temperature exposure acceptable up to 72 hours but should be refrigerated promptly.
What to Expect
- •Week 1-2: IGF-1 levels begin to rise, possible improved sleep quality
- •Week 2-4: Enhanced body composition changes begin, increased energy
- •Week 4-8: Visible muscle tone improvements, fat reduction, skin quality enhancement
- •Week 8-12: Sustained body composition improvements, optimal IGF-1 elevation
- •Month 3-6: Maximum benefits including muscle growth, fat loss, and anti-aging effects
Side Effects & Safety
Side Effects
- •Monitor thyroid function - 6.5% develop hypothyroidism requiring hormone replacement
- •Check IGF-1 levels monthly initially, then every 3-6 months long-term
- •Injection site reactions occur in 16.7% of patients but are generally mild
- •Contraindicated in active malignancy, pituitary tumors, and pregnancy
When to Stop
- •Signs of infection at injection site
- •Thyroid function abnormalities
- •Active cancer diagnosis
- •Pituitary issues
- •Consult healthcare provider
References
4 StudiesElderly Body Composition Study (1997)
Human | 19 adults 55-71 years | 16 weeks | Nightly injections | +1.26kg lean mass (males), elevated IGF-1 within 2 weeks
Study showing sermorelin can increase lean body mass and reduce body fat in elderly. Male subjects averaged nearly 3 pounds of lean mass gains with significantly elevated IGF-1 levels.
Cognitive Function Research
Elderly subjects | Several months nightly injections | Partial cognitive amelioration
Research in Dialogues in Clinical Neuroscience demonstrated preliminary evidence that sermorelin could 'partially ameliorate' cognitive declines stemming from deficient growth hormone and IGF-1 levels.
FDA Approval Study - Pediatric GH Deficiency
Children | 30mcg/kg daily | 36 months | 110 prepubertal GH-deficient children
Pivotal Geref International Study Group trial demonstrating sustained efficacy. Height velocity improved from 4.1 to 8.0 cm/year over 36 months of treatment.
View StudyQuick Start Guide
Research Disclaimer
Sermorelin is sold for laboratory research purposes only and is not intended for human or animal consumption. The information provided on this page is compiled from published research, veterinary studies, and anecdotal reports for educational purposes. This content does not constitute medical advice, diagnosis, or treatment recommendations. Any research involving Sermorelin must comply with all applicable local, state, and federal regulations. BioInfinity Lab makes no claims regarding the safety or efficacy of Sermorelin for any purpose. Consult qualified professionals for any research applications.